Oscar Tahuahua/X
Jun 13, 2025, 10:00
Oscar Tahuahua: Successful Surgical Conversion with T-DXd and PD-1 in ERBB2-Mutant NSCLC
Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, shared a post on X about a paper by Ruijie Zhang et al. published in npj | precision oncology:
“Stage IIIB ERBB2-mutant NSCLC (PD-L1 50%) treated with 3 cycles of T-DXd + PD-1 inhibitor led to 58% tumor shrinkage, pCR, R0 resection and MRD (-). No CRT needed. Recurrence-free at 9 months. First report of successful surgical conversion with this combo.”
Title: Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation
Authors: Ruijie Zhang, Sida Cheng, Kunkun Sun, Lihong Zhang, Xiang Yan, Fan Yang.
You can read the Full Article in npj | precision oncology.
More posts featuring Oscar Tahuahua.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 13, 2025, 09:43
Jun 13, 2025, 09:06
Jun 13, 2025, 08:53
Jun 13, 2025, 08:45